[American Heart Association](https://www.heart.org)

January 19, 2026 (Letter of Intent) | March 23, 2026 (Full Application, invited only)

Up to $300,000 per award (2 years; includes 10% indirect costs); up to 5 awards; optional AWS credits up to $30,000 for computational needs.

Funds research on the effects of GLP-1/GIP agonists in reducing cardiovascular, kidney, and metabolic disease burden using advanced data analytics.

--- ## Description This opportunity supports research investigating the impact of GLP-1 and GIP receptor agonists on individuals with cardiovascular, kidney, and metabolic (CKM) disease and/or obesity. The program seeks innovative projects that use advanced analytic methods—such as causal inference, machine learning, and population modeling—to evaluate medication initiation, adherence, dose escalation, and discontinuation patterns, as well as treatment effects, health outcomes, and cost-effectiveness. Projects should leverage large-scale data sources (e.g., de-identified claims, EHRs, cohort studies) and aim to quantify heterogeneity in drug response, project population health impact, and assess how these therapies may influence health inequities. Multidisciplinary collaborations are encouraged. --- ## Due Dates - **Letter of Intent (required):** January 19, 2026, by 3:00 PM CT - **Full Application (invited applicants only):** March 23, 2026, by 3:00 PM CT --- ## Funding Amount - **Total Award:** Up to $300,000 per project (includes up to 10% indirect costs) - **Duration:** Up to 2 years - **Number of Awards:** Up to 5 anticipated - **Additional Support:** Optional AWS credits up to $30,000 for projects using the AHA Precision Medicine Platform --- ## Eligibility - **Project Lead:** Must be an American Heart Association Professional Member (membership must be active before submission). - **Institution:** Must be a U.S.-based academic or non-profit organization. Preference for institutes of higher education, public entities, or 501(c)(3) nonprofits (not private foundations or Type III supporting organizations). Other nonprofits and for-profits may apply but may require additional documentation. - **Collaborators:** Multidisciplinary teams and multiple proposals from the same investigator are allowed (each proposal requires a separate LOI). - **Citizenship/Residency:** U.S. citizenship is not required, but the host institution must be U.S.-based. - **Other:** No scientific or budgetary overlap with other Heart Association or external funding. --- ## Application Process ### Letter of Intent (LOI) - **Required for all applicants** - **Due:** January 19, 2026, via [ProposalCentral](https://professional.heart.org/en/research-programs/aha-proposalcentral) - **Content:** Project title, lead/contact, co-investigators, collaborating organizations, data sources/statistical plan, budget estimate, and approach (2-page limit) ### Full Application (by invitation only) - **Invited after LOI review** - **Due:** March 23, 2026, via [ProposalCentral](https://professional.heart.org/en/research-programs/aha-proposalcentral) - **Components:** Up to 6-page research plan, works cited, detailed budget, and supporting documents - **Review:** Peer review by a multidisciplinary panel including data scientists and public health experts --- ## Additional Information - **Precision Medicine Platform:** Optional, not required. Provides secure cloud-based workspaces, tools for R/Python/SAS, and AWS credits for computational needs. - **Data Sharing:** Awardees must make factual data available in an AHA-approved repository or the Precision Medicine Platform. - **Open Access:** Publications must be made freely available in PubMed Central within 12 months. - **Progress Reports:** Required at mid-point and conclusion of the award. - **Compliance:** Awardees and their institutions must adhere to all AHA research policies, including those governing intellectual property and open science. --- ## External Links - [Program Page & RFP Details](https://professional.heart.org/en/research-programs/aha-funding-opportunities/glp1-medications-in-people-with-ckm-disease) - [Full RFP PDF](https://professional.heart.org/en/-/media/PHD-Files/Research/Funding-Opportunities-Media-Folder/Effects-of-GLP1-Medications-Among-Individuals-with-CKM-Disease.pdf?sc_lang=en) - [ProposalCentral Application Portal](https://professional.heart.org/en/research-programs/aha-proposalcentral) - [Application Resources & Guidelines](https://professional.heart.org/en/research-programs/application-resources) - [AHA Precision Medicine Platform](https://pmp.heart.org/) - [AHA Funding Opportunities Overview](https://professional.heart.org/en/research-programs/aha-funding-opportunities) --- ## Contact Information | Purpose | Contact | |---------------------------------|-----------------------------------------------------| | General Program & Eligibility | [apply@heart.org](mailto:apply@heart.org) | | Data Science/Platform Inquiries | [datascience@heart.org](mailto:datascience@heart.org)| | ProposalCentral Tech Support | pcsupport@altum.com, 1-800-875-2562 | | AHA Membership | 1-888-242-2453 or 972-349-5803 | | Main AHA Contact | +1 800-242-8721 | ---

Identifying the Effects of GLP-1 Medications Among Individuals with CKM Disease

Sign in to see full grant listing